NRX Pharmaceuticals (NRXP) Stock Forecast: StockMap's 2-Week Call
NRXP stock forecast: StockMap's model leans Underperform on NRX Pharmaceuticals for the two weeks after the Nov 19 close, toward NRXP trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 6 of 6 two-week windows on NRXP since Aug 21; by chance, a call on the same dates was right 60% of the time.
NRX Pharmaceuticals last closed at $2.55, -8.93% on the session.
Against the IVW growth benchmark the position is -6.60% over the forecast window.
NRX Pharmaceuticals' market cap is $113.03M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -33 (too close to call).
Where NRXP sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
44 daily calls for NRXP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks NRX Pharmaceuticals in the 97th percentile on return on equity, where 100 is best.
NRX Pharmaceuticals is classified under Health Care / Pharmaceuticals.
StockMap tracks NRX Pharmaceuticals as the 99th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite NRX Pharmaceuticals ranks 73rd of 153 in the group, against a group median of -0.36.